Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc. (Nasdaq: RPTX) is a clinical-stage precision oncology company whose news flow centers on synthetic lethality-based cancer drug development, portfolio monetization, and a planned acquisition by XenoTherapeutics, Inc. Company press releases describe a pipeline that includes RP-3467, a Phase 1 Polθ ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor, as well as prior development of the PKMYT1 inhibitor lunresertib. News items frequently cover updates on the POLAR and LIONS clinical trials, scientific presentations, and strategic transactions.
Investors and researchers following RPTX news can expect detailed announcements on clinical trial milestones, such as enrollment updates and initial safety, tolerability and early efficacy data from Phase 1 studies. Repare’s disclosures also highlight licensing and collaboration agreements, including an exclusive worldwide license of lunresertib to Debiopharm and an out-licensing of discovery platforms and intellectual property to DCx Biotherapeutics. Additional coverage includes the asset purchase agreement with Gilead Sciences for the Polθ ATPase inhibitor RP-3467 and amendments to collaboration arrangements with partners such as Bristol-Myers Squibb.
A significant portion of recent news focuses on Repare’s strategic review and corporate transactions. The company has announced a definitive arrangement agreement under which XenoTherapeutics, Inc. and Xeno Acquisition Corp. will acquire all of Repare’s common shares through a court-approved plan of arrangement. Related releases describe expected cash consideration per share, the issuance of non-transferable contingent value rights, support and voting agreements with major shareholders, and anticipated delisting from the Nasdaq Global Select Market following closing.
This news page aggregates these company-issued updates, including business highlights, quarterly financial results, conference abstracts and presentations, and regulatory disclosures referenced in Form 8-K filings. Readers interested in RPTX can use this stream to monitor developments in Repare’s precision oncology programs, its partnerships, and the progress of the proposed acquisition and associated contingent value right structure.
Repare Therapeutics announced the dosing of the first patient in its Phase 1 clinical trial of RP-6306, a novel small molecule targeting PKMYT1, six months ahead of schedule. This trial aims to assess the safety and tolerability of RP-6306 in treating cancers with CCNE1 amplification and other genomic mutations. Approximately 70 patients will be enrolled, with the intent to establish dosing for a planned Phase 2 program. RP-6306 is positioned as a first-in-class treatment, potentially addressing a significant gap in therapies for patients with specific altering tumors.
Repare Therapeutics (Nasdaq: RPTX) announced that its senior management team will present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on April 20 at 9:30 a.m. ET. Investors can access a live webcast of the presentation through the Company’s website, with a replay available for 30 days following the event.
The Company specializes in precision oncology using a proprietary synthetic lethality approach, with notable products in development, including the ATR inhibitor RP-3500 and the PKMYT1 inhibitor RP-6306.
Repare Therapeutics (RPTX) hosted a virtual Investor Day to discuss progress on RP-6306, a selective oral PKMYT1 inhibitor for tumors with CCNE1 amplification. The Company aims to start a Phase 1 clinical trial in Q2 2021, ahead of schedule. Key highlights include compelling pre-clinical data supporting RP-6306's efficacy as a monotherapy and in combination therapies. Repare's CRISPR-based SNIPRx platform identified PKMYT1 as a significant target for cancers resistant to existing treatments, addressing a rising unmet medical need in oncology.
Repare Therapeutics (Nasdaq: RPTX) will host a virtual Investor Day on April 8, 2021, from 10:30 a.m. to 12:00 p.m. ET. The event will feature discussions on RP-6306, a novel inhibitor targeting CCNE1 amplification, with a Phase 1 clinical trial expected to commence in Q2 2021, a quarter ahead of prior guidance. The trial aims to evaluate safety and establish the recommended Phase 2 dose for patients with recurrent CCNE1 amplified tumors. Repare leverages its SNIPRx platform to develop targeted cancer therapies.
Repare Therapeutics Inc. (Nasdaq: RPTX) announced the establishment of Automatic Securities Disposition Plans (ASDPs) by its Executives, Steve Forte and Maria Koehler. These plans comply with U.S. and Canadian securities regulations, allowing orderly share sales while preventing insider trading. Up to 42,182 shares may be sold under these ASDPs over approximately 14 months. Sales will commence post the filing of Form 10-Q for Q1 2021. The ASDPs include restrictions to mitigate risks associated with material non-public information and allow only one plan per Executive.
Repare Therapeutics (Nasdaq: RPTX) reported its financial results for Q4 and full year 2020, highlighting strong capital raising and clinical progress.
The company secured over $300 million, advancing its Phase 1/2 trial for RP-3500. They activated 10 clinical sites across North America and Europe for the trial. Repare also initiated IND-enabling studies for RP-6306 and expects to launch its trial by Q2 2021, earlier than planned. However, the company reported a net loss of $53.4 million for the year, a significant increase from $27.2 million in 2019.
Repare Therapeutics (Nasdaq: RPTX), a clinical-stage precision oncology company, announced participation in three virtual investor conferences in March 2021. Key events include the Cowen 41st Annual Healthcare Conference on March 2, focusing on ovarian cancer, and the H.C. Wainwright Global Life Sciences Conference on March 9-10. Additionally, Repare will attend the Morgan Stanley Virtual Healthcare Corporate Access Day on March 16. The H.C. Wainwright presentation will be available for replay on the Company’s website for 30 days, showcasing its innovative cancer therapies and pipeline development.
Repare Therapeutics, Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced CEO Lloyd M. Segal's participation in two virtual investor conferences. The H.C. Wainwright Virtual BioConnect Conference will be from January 11-14, 2021, with a pre-recorded presentation available on January 11 at 6:00 a.m. ET. The 39th Annual J.P. Morgan Healthcare Conference is scheduled for January 14, 2021, at 8:20 a.m. ET, featuring a live webcast. Repare focuses on developing targeted cancer therapies through its SNIPRx® platform, with notable products like RP-3500.
Repare Therapeutics (Nasdaq: RPTX) has announced the implementation of Automatic Securities Disposition Plans (ASDPs) by its executives and other insiders, allowing for the orderly sale of their shares over the next 12 to 24 months. The ASDPs comply with U.S. and Canadian securities laws, ensuring trades occur without access to undisclosed material information. A total of 439,272 common shares may be sold under these plans, with established trading parameters exceeding current market prices.
Repare Therapeutics (Nasdaq: RPTX) has announced its addition to the NASDAQ Biotechnology Index, effective December 21, 2020. This is a significant milestone for the company, renowned for its innovative synthetic lethality approach in oncology. The NASDAQ Biotechnology Index tracks the performance of biotechnology and pharmaceutical companies listed on NASDAQ, ensuring those meet specific market value and trading volume criteria. Repare's SNIPRx® platform is pivotal in developing targeted cancer therapies, including its lead candidate RP-3500, an ATR inhibitor.
FAQ
What is the current stock price of Repare Therapeutics (RPTX)?
What is the market cap of Repare Therapeutics (RPTX)?
